CPC technology class · C08

C08B - Polysaccharides

Polysaccharides; derivatives thereof. 3,742 US utility patents granted 2015–2025, with the leading assignees and year-by-year grant trajectory.

Compiled by PlainPatent · May 15, 2026

3,742
US patents granted: #6/8
in C08: 2.6%
C08 class share: -2%
5-yr velocity

The verdict

According to USPTO PatentsView, Polysaccharides ranks #285 of 670 CPC technology areas - 3,742 US patents granted since 2015, with recorded grant volume down 2% over five years.

#285
of 670 CPC technology areas: 3,742
US patents granted, 2015–2025: Axsome Therapeutics
leading assignee (72): -2%
grant velocity, last 5 yrs

How C08B's grant cadence moved

Between 2020–2024, C08B recorded 1,595 grants versus 1,629 in 2015–2019 (-2% equal-window velocity). Across complete years, output peaked in 2019 at 383 grants and bottomed in 2024 at 272 (+41% peak-over-trough). Lead assignee Axsome Therapeutics, Inc. holds 1.9% of the class ; the top three share 4.4%.

Leaderboard read

C08B concentration, lead at 1.9%

Axsome Therapeutics, Inc. leads this historical grant record at 1.9% of C08B - foreign corporation assignees hold 57% of class grants (986 of 1,735). Figures describe granted US utility patents in this CPC subclass, not current investment or legal strength.

Leader's share: 1.9%
Top three share: 4.4%
Lead over #2: 21

Where C08B sits inside C08

Among 8 subclasses in C08 (Organic Macromolecular COMPOUNDS; Their Preparation OR Chemical WORKING-UP; Compositions Based Thereon), C08B ranks #6 and holds 2.6% of the parent class's 144,472 recorded grants. Sibling chips below are the other subclasses in the same parent class, not the nationwide volume/lead-share peers further down.

C08L 36,183 C08G 29,133 C08K 28,505 C08F 23,159 C08J 21,338 C08C 1,240 C08H 1,172

Rising assignees active in C08B

Company-wide grant multiples (2022–2024 vs 2019–2021) among assignees with ≥5 patents in this subclass. Growth is company-wide; class patent counts are subclass-specific.

#1 Cambridge Glycoscience Ltd 6.00x 1 → 6 company-wide · 6 in C08B
#2 Ynsect 4.00x 2 → 8 company-wide · 6 in C08B
#3 ICM, Inc. 3.40x 5 → 17 company-wide · 5 in C08B
#4 Treetotextile AB 3.00x 1 → 3 company-wide · 6 in C08B
#5 Integrity Bio-Chemicals, LLC 2.67x 3 → 8 company-wide · 6 in C08B

C08B grants by year, peak 2019 (383)

US utility-patent grants per year in C08B, 2015–2025 - recent five years are down 2% versus 2015–2019.

Axsome Therapeutics

72
Nutrition & Bioscience…

51
Xyleco

43
Eastman Chemical

35
Daicel

33
Nippon Paper…

30
Cargill Incorporated

29
Galderma Holding

28
Jiangnan University

27
Oji Holdings

26
Cydex Pharmaceuticals

24
Dupont Industrial…

24

What this shows Axsome Therapeutics is the most active filer in C08B, holding 72 of the 3,742 patents in this class. Concentration at the top signals how contestable this technology area is for new entrants.

View data table

Top patent holders in CPC subclass C08B
Rank	Company	Patents in C08B
#1	Axsome Therapeutics, Inc.	72
#2	Nutrition & Biosciences USA 4, Inc.	51
#3	Xyleco, Inc.	43
#4	Eastman Chemical Company	35
#5	Daicel Corporation	33
#6	Nippon Paper Industries Co., Ltd.	30
#7	Cargill, Incorporated	29
#8	Galderma Holding SA	28
#9	Jiangnan University	27
#10	OJI Holdings Corporation	26
#11	CyDex Pharmaceuticals, Inc.	24
#12	DuPont Industrial Biosciences USA, LLC	24
#13	Glaxosmithkline Biologicals SA	23
#14	Corn Products Development, Inc.	22
#15	Stora Enso OYJ	21
#16	Upm-kymmene Corporation	20
#17	Fidia Farmaceutici S.p.A.	20
#18	Lenzing Aktiengesellschaft	19
#19	Roquette Freres	18
#20	Seikagaku Corporation	16

Footprint here vs. claim strategy

Each dot is a leading C08B assignee, placed by how many patents it holds in this class (horizontal) against its company-wide average claims per patent (vertical) - a read on whether the class is led by broad-but-shallow filers or focused deep-claim players.

Top 14 C08B assignees by class footprint. Bubble size = patents in C08B. Source: USPTO PatentsView (claim depth is company-wide across all classes).

Classes near C08B's 3,742-grant footprint

Nationwide nearest neighbors for C08B (#285 of 670 by volume ; lead share 1.9%) - not the C08 parent-class siblings above.

Nearest by grant volume

F42B 3,745 B62M 3,735 B26D 3,757 A01C 3,761

Nearest by lead-assignee share

C12N 1.9% G01M 2.0% G01B 2.0% Y02B 1.9%

Questions about C08B

Which company holds the most patents in C08B?

Axsome Therapeutics, Inc. leads C08B with 72 patents (1.9% of the subclass). By PatentsView assignee type, foreign corporations account for 57% of class grants.

Which C08B assignees grew fastest recently?

Among assignees with ≥5 grants in C08B, Cambridge Glycoscience Ltd shows the highest company-wide grant multiple (6.00x: 1 grants in 2019–2021 → 6 in 2022–2024) while holding 6 patents in this subclass. Growth is company-wide, not class-only.

How does C08B compare inside parent class C08?

Inside C08 (Organic Macromolecular COMPOUNDS; Their Preparation OR Chemical WORKING-UP; Compositions Based Thereon), C08B ranks #6 of 8 subclasses by grant volume and holds 2.6% of the parent class total. The largest sibling is C08L (36,183 grants).

What to do with this data

C08B in context - here's where to go next.

Axsome Therapeutics, Inc. leads C08B with 72 grants in this class. See full portfolio
C08B ranks #285 of 670 by grant volume among all tracked CPC technology areas. See the ranking
Inside parent class C08, the largest sibling subclass is C08L with 36,183 grants. Explore C08L

Figures reflect USPTO PatentsView grant data through 2026-05-15; pending applications not yet granted are not counted.

Methodology - C08B figures are USPTO PatentsView granted-utility totals for this subclass (3,742 grants in the tracked window).

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.